Replimune Group, Inc. (REPL)
6.98
+0.09
(+1.31%)
USD |
NASDAQ |
Mar 20, 16:00
7.00
+0.02
(+0.29%)
After-Hours: 20:00
Replimune Group Research and Development Expense (Quarterly) : 52.87M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| REGENXBIO, Inc. | 55.74M |
| ANI Pharmaceuticals, Inc. | 12.26M |
| Phathom Pharmaceuticals, Inc. | 7.493M |
| Catalyst Pharmaceuticals, Inc. | 1.807M |
| Sarepta Therapeutics, Inc. | 319.50M |